Lynparza Tablet, Film Coated
Product Images NDC 0310-0679

14 FDA label images from Astrazeneca Pharmaceuticals Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Lynparza (NDC 0310-0679). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 6

Figure 6
A Kaplan-Meier survival curve depicting the percentage of patients alive and invasive disease free over time, comparing olaparib 300 mg twice daily to placebo. The x-axis represents months since randomization, and the y-axis shows the percentage of patients. A table below the graph indicates the number of patients at risk at various time points for both treatment groups.*
FDA Label Image

Figure 7

Figure 7
A Kaplan-Meier survival curve comparing the percentage of patients alive over time in months since randomization for Olaparib 300 mg twice daily versus placebo. The plot shows patient survival rates on the y-axis from 0% to 100%, and time in months on the x-axis, extending to approximately 90 months. A table below lists the number of patients at risk for each group at specified monthly intervals.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A Kaplan-Meier survival curve chart comparing the proportion of patients event-free over time (in months) between Olaparib 300 mg twice daily tablets and placebo twice daily tablets. The chart includes patient numbers at risk across time points up to 60 months, showing higher event-free survival with Olaparib compared to placebo.*
FDA Label Image

Figure_7 (Figure 7)

Figure_7 (Figure 7)
A Kaplan-Meier plot showing the probability of radiological progression-free survival over time in months from randomization. The chart compares Olaparib 300 mg bd (N=162) and Enzalutamide or abiraterone acetate (N=83). The y-axis represents the probability of progression-free survival, and the x-axis represents time from randomization in months. The graph includes a table below showing the number of patients at risk at various time points for each treatment group.*
FDA Label Image

Figure_8 (Figure 8)

Figure_8 (Figure 8)
A Kaplan-Meier survival curve chart depicting the probability of overall survival over time (months) from randomization in two patient groups: one receiving Olaparib 300 mg bd (N=162) and the other receiving Enzalutamide or abiraterone acetate (N=83). The chart includes survival curves and a table showing the number of patients at risk at various time points for both groups.*
FDA Label Image

Checmical Structure (Image 01)

Checmical Structure (Image 01)
Chemical structure of olaparib, the active ingredient in Lynparza tablets, shown as a molecular diagram illustrating its atomic bonds and ring systems.*
FDA Label Image

Figure 3 (Image 02)

Figure 3 (Image 02)
A survival analysis line graph comparing Lynparza (olaparib) 300 mg twice daily tablet versus placebo twice daily tablet. The graph shows the proportion of patients event free over time from randomization in months, with Lynparza maintaining a higher event-free proportion than placebo throughout the approximately 33-month follow-up period. A table below the graph lists the number of patients at risk in each group over time.*
FDA Label Image

Figure 4 (Image 03)

Figure 4 (Image 03)
A Kaplan-Meier survival curve comparing event-free proportions over time between patients taking olaparib 400 mg twice daily capsules and those taking placebo twice daily capsules. The x-axis shows time from randomization in months, and the y-axis represents the proportion of patients event-free. The graph also includes a table indicating the number of patients at risk at various time points for each treatment group.*
FDA Label Image

Figure 5 (Image 04)

Figure 5 (Image 04)
A Kaplan-Meier survival curve comparing 'Olaparib 300 mg twice daily tablet' to 'Chemotherapy' over 28 months from randomization. The y-axis represents the proportion of patients event free, while the x-axis shows time in months. Patient numbers at risk are listed below the graph for each group at successive time points.*
FDA Label Image

Figure 6 (Image 05)

Figure 6 (Image 05)
A Kaplan-Meier plot depicting the probability of progression-free survival over time (up to 46 months) for patients taking Olaparib 300 mg twice daily tablets versus placebo twice daily tablets. The x-axis shows time from randomization in months, and the y-axis shows the probability of progression-free survival. A table below the graph lists the number of patients at risk at various time points for both treatment groups.*
FDA Label Image

Figure 2 (Image 06)

Figure 2 (Image 06)
A Kaplan-Meier curve illustrating the proportion of patients event-free over time from randomization (in months) comparing two groups: Olaparib + bevacizumab and Placebo + bevacizumab. The graph shows patient counts at risk at various time points below the x-axis, indicating the sample size declining over time for each group.*
FDA Label Image

Figure 4 (Image 07)

Figure 4 (Image 07)
A Kaplan-Meier survival curve showing the proportion of patients event-free over time (months) comparing Olaparib 300 mg twice daily tablets versus placebo twice daily tablets. The graph includes a table of the number of patients at risk at various time points for both treatment groups.*
FDA Label Image

Lynparza_100mg_60tablet_bottle_label (Lynparza 100mg 60tablet Bottle Label)

Lynparza_100mg_60tablet_bottle_label (Lynparza 100mg 60tablet Bottle Label)
Lynparza 100 mg (olaparib) film-coated tablets label from AstraZeneca Pharmaceuticals LP. The label indicates this is a prescription drug with 60 tablets per package. It includes instructions to dispense a Medication Guide with each patient.*
FDA Label Image

Lynparza_150mg_120_tablet_bottle_label (Lynparza 150mg 120tablet Bottle)

Lynparza_150mg_120_tablet_bottle_label (Lynparza 150mg 120tablet Bottle)
Lynparza (olaparib) 150 mg tablets film-coated, oral use, in a carton labeled by AstraZeneca Pharmaceuticals LP. The package contains 120 tablets with the instruction to dispense the accompanying medication guide to each patient. The label includes NDC 0310-0679-12 and states Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.